Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2025-12-26 @ 2:11 AM
Study NCT ID:
NCT03912805
Status:
COMPLETED
Last Update Posted:
2022-07-28
First Post:
2019-04-10
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
Sponsor:
Eirion Therapeutics Inc.
Organization:
Study Overview
Official Title:
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Detailed Description:
This product is being tested for its ability to reduce lateral canthal lines (LCL), also known as Crow's Feet.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: